---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-21-000048"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2021-08-02T23:59:59+00:00"
generated_at: "2026-06-29T23:59:36.141965+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics appoints Simon Cooper as CMO effective Aug 2; Ordonez departs

## Summary
- Simon Cooper appointed CMO effective Aug 2, 2021; succeeds Claudia Ordonez who departed July 30.
- Dr. Cooper previously SVP/CMO at Kadmon; prior roles at Anokion, AbbVie, Sanofi, Novartis.
- Ordonez gets 9-month base salary severance, acceleration on 7,603 options, COBRA up to 9 months, $5k consulting fee.
- Cooper receives $450k base salary, 40% target bonus, option for 60,000 shares.

## SEC filing metadata
- accession: 0001664710-21-000048
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2021-08-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/0001664710-21-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/keros-form8xk.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-21-000048
- JSON: https://secwatch.observer/filing/0001664710-21-000048.json
- Plain text: https://secwatch.observer/filing/0001664710-21-000048.txt

## Key facts
- Executive change
  Simon Cooper was appointed as Chief Medical Officer at Keros Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/0001664710-21-000048-index.htm
- Executive change
  Claudia Ordonez departed as Chief Medical Officer at Keros Therapeutics, Inc..
  - Action: departed
  - Role: Chief Medical Officer
  source text: Dr. Cooper is succeeding Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/0001664710-21-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.